Lung Cancer Considered

As part of the IASLC's ongoing series of podcasts in world languages, this episode brings together two leading lung cancer experts who discuss training and education in medical oncology and lung cancer in Arabic. Host: Dr. Nagla Abdel Karim Thoracic Medical Oncologist, Director of Developmental Therapeutics at Inova Schar Cancer Institute Professor of Medicine at the University of Virginia School of Medicine Guest: Dr. Rami Manochakian, FASCO Associate Professor of Medicine and Consultant, Thoracic Oncology Mayo Clinic Florida

In this episode of Lung Cancer Considered, host Dr. Stephen Liu moderates a discussion about the management of relapsed SCLC, which remains a very challenging cancer to treat, despite recent progress. Guest: Dr. Malinda Itchins is a Medical Oncologist at Royal North Shore Hospital, Visiting Medical Officer for Thoracic Cancers at Chris O’Brien Lifehouse, and Faculty at the University of Sydney. She is the Board Director and Lung Cancer Chair for the Clinical Oncology Society of Australia (COSA) and the Scientific Committee Advanced NSCLC Group Co-Chair for the Thoracic Oncology Group of Australasia (TOGA). Guest: Dr. Jacob Sands is an Assistant Professor at Harvard Medical School and Thoracic Medical Oncologist at the Lowe Center for Thoracic Oncology at the Dana Farber Cancer Institute, where he leads the Clinical Research Program in SCLC. Jacob is also Co-founder and President of the Rescue Lung Society, a 501(c)3 society focused on advancing lung cancer screening.

Lung Cancer Considered--Managing ADC Toxicities by IASLC

Host Dr. Narjust Florez previews the 2024 Latin America Lung Cancer Meeting with co-chairs Dr. Lucia Viola, Dr. Andres Feliple Cardona and Dr. Stella Martinez. LALCA is a dynamic meeting with a long tradition that features the most up-to-date research, diverse topics of interest, and educational sessions with leading experts. Guest: Dr. Lucia Viola Interventional Pulmonologist- Head of Thoracic Oncology Service. She is a member of the Fundación Neumológica Colombiana - Fundación CTICGuest: Dr. Andrés Felipe Cardona is the Director of Research, Science and Education of the Luis Carlos Sarmiento Angulo Cancer Treatment and Research Center (CTIC) located in Bogotá, Colombia. Guest: Dr. Stella Martinez is an Associate Professor of thoracic Surgery and Director of the Specialization Program in Thoracic Surgery at El Bosque University in Bogotá, Colombia.

The 2024 World Conference on Lung Cancer brings together leading experts, researchers, and oncologists to showcase the latest advancements in lung cancer research and celebrate IASLC’s 50th anniversary. To reach a global audience, IASLC has recorded podcast episodes on WCLC 2024 in world languages. In this episode, host Dr. Nagla Abdel Karim moderates a discussion in Arabic about highlights from the conference with Dr. Fawzi Abu Rous, Dr. Raid Aljumaily, Dr. Abdulaziz AlJassim, and Dr. Ashraf Mohamed. Host: Dr. Nagla Abdel Karim Thoracic Medical Oncologist, Director of Developmental Therapeutics at Inova Schar Cancer Institute Professor of Medicine at the University of Virginia School of Medicine Guests: Dr. Fawzi Abu Rous Thoracic Medical Oncologist Henry Ford Health, Detroit, MI Dr. Raid Aljumaily Associate Professor of Medicine University of Oklahoma Dr. Abdulaziz AlJassim Senior Specialist in Thoracic Medical Oncology and Internal Medicine. Kuwait Cancer Control Center, Kuwait Dr. Ashraf Mohamed Director of Surgery Business Development Siemens Healthineers

This episode of Lung Cancer Considered covers the recently completed 2024 ESMO Congress in Barcelona. Host Dr. Stephen Liu discussed the important research presented at the meeting with Dr. Marina Garassino and Dr. Federico Cappuzzo.

Description: The FDA approved amivantamab therapy for EGFR mutant NSCLC after progression on osimertinib. This approval is based on the phase III MARIPOSA-2 trial, with data first shared at ESMO 2023 in Madrid with a simultaneous publication in the Annals of Oncology. Lung Cancer Considered host Dr. Stephen Liu talks with two leading oncologists to learn more about how this therapy will be used by clinicians Guest: Dr. Karen Reckamp, Professor of Medicine, Director of the Division of Medical Oncology, and Associate Director of Clinical Research at Cedars-Sinai Medical Center Guest: Dr. William Nassib William, National Leader of Thoracic Oncology at Oncolinicas, Sao Paulo, Brazil

In a special episode of Lung Cancer Considered, host Dr. Stephen Liu discuss the recent FDA approval of pembrolizumab plus platinum and pemetrexed for mesothelioma, based on the phase III KEYNOTE 483 study. Guest: Dr. Ibiayi Dagogo-Jack is a thoracic oncologist from Massachusetts General Hospital and Assistant Professor at Harvard Medical School Guest: Dr. Quincy Chu is a thoracic oncologist at the University of Alberta Cross Cancer Institute’s New Drug Development Program and CCTG Investigational New Drug Committee Chair

In this episode of Lung Cancer Consider, host Dr. Stephen Liu previews the upcoming IASLC 2024 Asia Conference on Lung Cancer with meeting co-chair, Dr. Feng-Ming (Spring) Kong.

The 2024 World Conference on Lung Cancer brings together leading experts, researchers, and oncologists to showcase the latest advancements in lung cancer research and celebrate IASLC’s 50th anniversary. To reach a global audience, IASLC has recorded podcast episodes on WCLC 2024 in world languages. In this episode, host Dr. Clarissa Mathias moderates a discussion in Portuguese about highlights from the conference with Dr. Isabella Favato Barcelos and Dr. William Nassib William. Guests: Dr. Clarissa Mathias Medical Oncologist at Oncoclinicas Bahia and Hospital Santa Izabel Dr. Isabella Favato Barcelos Medical Oncologist, Oncoclinicas&Co/MedSir, Brazil Dr. William Nassib William National Leader of Thoracic Oncology at Oncolinicas, Sao Paulo, Brazil

In this special episode of Lung Cancer Considered, Stephanie McDonald and Jillian Thompson discuss their perspectives of attending the 2024 World Conference on Lung Cancer as nurse practitioners. Hear their favorite sessions, their observations as first-time attendees, and why they hope to see more nurse practitioners at future IASLC events. Guests: Jillian Thompson, MSN, ANP-BC, AOCNP Nurse Practitioner MedStar Georgetown University Hospital Lombardi Comprehensive Cancer Center Stephanie McDonald RN, MSN, FNP-BC, AOCNP Nurse Practitioner Dana-Farber Cancer Institute

The 2024 World Conference on Lung Cancer brings together leading experts, researchers, and oncologists to showcase the latest advancements in lung cancer research and celebrate IASLC’s 50th anniversary. To reach a global audience, IASLC has recorded podcast episodes on WCLC 2024 in world languages. In this episode, host Dr. Coral Olazagasti moderates a discussion in Spanish about highlights from the conference with Dr. Maria Velez and Dr. Rossana Ruiz. Guests: Dr. Coral Olazagasti Assistant Professor at the Sylvester Cancer Center, University of Miami at Miami, Florida. Dr. Rossana Ruiz Medical Oncologist from Universidad Peruana Cayetano Heredia Global Health Fellowship at MGH in Boston, Massachusetts Thoracic Medical Oncologist, Instituto Nacional de Enfermedades Neoplasicas and AUNA-Oncosalud in Lima, Peru Dr. Maria Velez Clinical Instructor, Division of Hematology-Oncology UCLA David Geffen School of Medicine in Los Angeles, California

In this special WCLC 2024 episode of Lung Cancer Considered, hosts Dr. Narjust Florez and Dr. Stephen Liu recap the conference and discuss the meeting's most impactful research. Dr. Jacob Sands discusses overall survival updates from TROPION-Lung01 with datopotamab deruxtecan and DeLLphi-301 with tarlatamab. Dr. Hidehito Horinouchi reports results from the LUMINOSITY study of telisotuzumab vedotin, and Dr. Noemi Reguart gives some perspective on TRUST-II with talectrectinib. The group discusses the biggest stories from WCLC 2024, their favorite moments, and a preview of WCLC 2025 in Barcelona, Spain. Guests: Dr. Hidehito Horinouchi Assistant Chief, Department of Thoracic Oncology, National Cancer Center Hospital, Tokyo General Secretary, Japan Clinical Oncology Group Dr. Noemi Reguart Clinical Professor at the University of Barcelona Coordinator of the Thoracic Oncology Unit, Hospital Clínic Barcelona, Spain WCLC 2025 Co-Chair Dr. Jacob Sands Assistant Professor of Medicine, Harvard Medical School Lowe Cancer Center for Thoracic Oncology Dana Farber Cancer Institute

The 2024 World Conference on Lung Cancer brings together leading experts, researchers, and oncologists to showcase the latest advancements in lung cancer research and celebrate IASLC’s 50th anniversary. To reach a global audience, IASLC has recorded podcast episodes on WCLC 2024 in world languages. In this episode, host Dr. Chunxia Su moderates a discussion in Mandarin about highlights from the conference with Dr. Huijuan Wang and Dr. Lin Wu. Guests: Dr. Chunxia Su Professor of Oncology at Tongji University Deputy Director of Medical Oncology at Shanghai Pulmonary Hospital Dr. Huijuan Wang Professor of Oncology Department of Medical Oncology The Affiliated Cancer Hospital of Zhengzhou University/Henan Cancer Hospital Dr. Lin Wu Director, Thoracic Oncology Department II Hunan Cancer Hospital, Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University

In this special WCLC 2024 episode of Lung Cancer Considered, host Dr. Narjust Florez discusses daily highlights from the conference. Dr. Xiuning Le reports updated results of BAY 292708, and Dr. Gerrina Ruiter summarizes the Beamion LUNG-1 study, both of which evaluate the efficacy of therapies for patients with HER2-Mutant NSCLC. Dr. Fiona Hegi-Johnson adds her perspective as a discussant of the POLESTAR trial evaluating EGFR therapy after chemoradiation in stage III unresectable NSCLC. Guests: Dr. Fiona Hegi-Johnson Radiation Oncologist at the Peter MacCallum Cancer Centre Senior Research Fellow at the University of Melbourne Dr. Xiuning Le, M.D., Ph.D. Assistant Professor in the Department of Thoracic/Head and Neck Medical Oncology University of Texas M.D. Anderson Cancer Center Dr. Gerrina Ruiter, M.D., Ph.D. Pulmonologist Specialized in Thoracic Oncology at the Netherlands Cancer Institute Amsterdam, The Netherlands

The 2024 World Conference on Lung Cancer brings together leading experts, researchers, and oncologists to showcase the latest advancements in lung cancer research and celebrate IASLC’s 50th anniversary. To reach a global audience, IASLC has recorded podcast episodes on WCLC 2024 in world languages. In this episode, host Dr. Chul Kim moderates a discussion in Korean about highlights from the conference with Dr. Jeongmin Seo and Dr. Jii Bum (Joy) Lee. Guests: Dr. Chul Kim, MD Associate Professor at Georgetown University with a focus on thoracic oncology Dr. Jeongmin Seo, MD Clinical Assistant Professor at Seoul National University Bundang Hospital with a focus on thoracic oncology Dr. Jii Bum (Joy) Lee, MD, PhD Yonsei Cancer Center, Yonsei University College of Medicine

In this special WCLC 2024 episode of Lung Cancer Considered, host Dr. Stephen Liu discusses daily highlights from the conference. Dr. Caicun Zhou discusses the results of ivonescimab versus pembrolizumab in the first-line HARMONi-2 study. Dr. Tina Cascone discusses preliminary outcomes from the perioperative NeoCOAST-2 study, and Dr. Marina Chiara Garassino outlines the potential QCS-NMR TROP2 biomarker using data from TROPION-Lung01. Dr. Matthew Smeltzer shares the results of the 2024 IASLC Global Survey on Biomarker Testing and how they compare to findings from the previous survey in 2018. Guests: Dr. Tina Cascone Physician-Scientist and Associate Professor, Department of Thoracic/Head and Neck Medical Oncology University of Texas MD Anderson Cancer Center in Houston, Texas Dr. Marina Chiara Garassino Director, Thoracic Oncology Program and Professor of Medicine University of Chicago Dr. Matthew Smeltzer Associate Professor, Division of Epidemiology, Biostatistics, and Environmental Health University of Memphis Professor Caicun Zhou Chief Physician and Director of the Department of Medical Oncology Tongji University in Shanghai Pulmonary Hospital

Description: To celebrate IASLC’s 50th Anniversary, IASLC produced podcasts looking at our past and present. In this podcast, host Dr. Narjust Florez peers into the future with a detailed discussion of the new IASLC Strategic Plan and how it will impact IASLC as well as the future of lung cancer care. Guest: Dr. Nick Pavlakis is a thoracic medical oncologist and professor of medicine at the University of Sydney. Guest: Dr. Gilberto Lopes is the Chief of the Division of Medical Oncology at Sylvester Comprehensive Cancer Center, Associate Director for the Cancer Center and Medical Director for International Affairs and Professor of Medicine at the University of Miami.

Description: This year marks the 50th anniversary of the International Association for the Study of Lung Cancer and as part of this celebratory year, we are looking at the past, present and future of the organization. In this episode of Lung Cancer Considered, host Dr. Stephen Liu and guests focus on IASLC today – and some of the ongoing efforts of the IASLC and its members. Guest: Dr. Christian Rolfo, Professor of Medicine, Director of Medical Oncology and Associate Director for Early Phase Clinical Trials at the Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University. Guest: Janet Freeman-Daily, Patient Research Advocate, Co-Founder and President of The ROS1ders, former Associate Editor of IASLC Lung Cancer News and co-developer of the IASLC STARS program. Guest: Dr. Emily Stone is a Consultant Respiratory Physician at St. Vincent’s Hospital in Sydney Australia, conjoint Professor at the University of New South Wales, past Chair of the IASLC Tobacco Control and Smoking Cessation Committee, Deputy Chair Thoracic Oncology Group of Australasia and current Editor in Chief of the JTO Clinical and Research Reports

In 1972, in response to the overwhelming need for collaboration and a growing concern for public health, Drs. David T. Carr, Oleg S. Selawry, Lawrence Broder, Clifton Mountain and George Higgins began building an international, multidisciplinary organization. In 1974, the group launched the International Association for the Study of Lung Cancer (IASLC) at their first formal meeting in Florence, Italy, having recruited more than 250 founding members from across the globe and with different perspectives. In today’s episode, host Dr. Narjust Florez talks with two of those early members who played influential roles in IASLC’s early growth and success: Dr. Paul Bunn and Dr. Fred Hirsch. Guest: Dr. Paul Bunn is a Distinguished Professor of Medicine and James Dudley Chair in Cancer Research, Division of Medical Oncology at the University of Colorado School of Medicine. Dr Bunn was President of the ASCO and he served as president and as CEO, of the International Association for the Study of Lung Cancer. Guest: Dr. Hirsch is the Executive Director at the Center for Thoracic Oncology in The Tisch Cancer Institute at Mount Sinai (TCI) and the Joe Lowe and Louis Price Professor of Medicine (Hematology and Medical Oncology) at the Icahn School of Medicine at Mount Sinai. Dr. Hirsch served as Chief Executive Officer of IASLC for five years.

Description: On August 19th, the Food and Drug Administration approved lazertinib in combination with amivantamab for the first-line treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R substitution mutations. In this episode of Lung Cancer Considered, host Dr. Narjust Florez talks with Dr. Julia Rotow about this therapy and the MARIPOSA trial, which evaluated the use of lazertinib in combination with amivantamab.. Guest: Dr. Julia Rotow, Clinical Director of the thoracic oncology group at Dana-Faber Cancer Institute, Assistant Professor of Medicine at Harvard Medical School.

As part of IALC's ongoing series of podcasts in world languages, this podcast brings together four of the leading Chinese lung cancer experts who discuss current research and clinical issues, in Mandarin. Host: Chunxia Su, M.D., PhD, Professor of Oncology, Doctoral Supervisor, School of Medicine, Tongji University Guest: Xiuning Le, MD, Department of Thoracic-Head & Neck Med Oncology, Division of Cancer Medicine, MD Anderson Guest: Jianming Ying, Professor & Director Department of Pathology National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences Guest: Professor Li Zhang, Director of the Department of Internal Medicine, Doctoral Supervisor, Second Class Professor, and Chief Expert on Lung Cancer at Sun Yat sen University Cancer Prevention and Treatment Center

Description: In this episode of Lung Cancer Considered, host (and WCLC 2024 Co-Chair) Dr. Narjust Florez previews the upcoming IASLC 2024 World Conference on Lung Cancer with the meeting’s other three co-chairs. Guest: Dr. Linda Martin, Professor of Surgery and Chief of Thoracic Surgery at the University of Virginia. Guest: Dr. Fabio Ynoe de Moraes, Chief of Global Radiation Oncology and Associate Professor of Radiation Oncology at Queen University. Guest: Dr. Sandip Patel, Professor of Medicine and Thoracic Medical Oncologist at the University of California San Diego.

In this episode of Lung Cancer Considered, host Dr. Narjust Florez moderates a discussion in Spanish about perioperative chemotherapy and immunotherapy and how recent research may affect clinical decision making in Latin America. Guest: Dr. Clarissa Baldotto graduated from the Fluminense Federal University and studied Clinical Oncology at the National Cancer Institute (INCA). She completed a Master's Degree in Clinical Cancerology at INCA and a PhD in Medical Sciences at the D'Or Institute for Research and Education (ID'Or). Guest: Dr. Paula Ugalde Figueroa graduated from the School of Medicine at the Federal University of Bahia in Salvador, BA, Brazil. With training in Brazil, the United States, and Canada, Dr. Ugalde has established herself as a research-driven thoracic surgeon. In 2021, she was appointed as a Director of the IASLC Board of Directors and continues to break barriers for many Latinas in oncology.

Seminal Trial Series: Crizotinib in PROFILE 1001 by IASLC

Lung Cancer Considered in Farsi.

In this episode of Lung Cancer Considered, host Dr. Narjust Florez and two esteemed oncology colleagues discuss an evolving hot topic: the use of immune checkpoint inhibitors in the treatment of patients with molecular driven non-small cell lung cancer. Guest: Dr. Erin Schenk is an Assistant Professor of Medicine in the section of Medical Oncology at the University of Colorado and the Director of the Schenk Laboratory X: @SchenkLab Guest: Dr. Biagio Ricciuti is a Thoracic Medical Oncologist and Data Scientist at Dana-Farber Cancer Institute and Harvard Medical School X: @BiagioRicciutMD

LCC In Greek by IASLC

In this episode of Lung Cancer Considered, host Dr. Narjust Florez moderates a discussion on the management of early-stage disease, with an eye toward applying conclusions from trials such as the ADAURA and the recent ESMO and ELCC data about perioperative chemo-immunotherapy.

Description: Host Dr. Narjust Florez and two esteemed international clinicians discuss the unique characteristics of CNS metastases in patients with non-small cell lung cancer and small cell lung cancer. Guest: Dr. Sarah Goldberg is an Associate Professor of Medicine in the section of Medical Oncology at the Yale School of Medicine. She is the Division Chief of Thoracic Oncology, the Research Director for the Center for Thoracic Cancers, and the Associate Program Director for the Medical Oncology-Hematology Fellowship Program at Yale Guest: Dr. Ernest Nadal is a medical oncologist and the director of Thoracic Tumors Section at the Catalan Institute of Oncology, an Associate Professor at the University of Barcelona, a vital member of the Spanish Lung Cancer Group and an expert in clinical trial development and interest in response and use of immune checkpoint inhibitors for the management of CNS metastases.

Continuing our series of podcasts in different world languages, this episode focuses on lung cancer research and treatment in Romanian. Host: Mihaela Aldea, MD PhD Thoracic Oncology and Precision Medicine Group Department of Medical Oncology Gustave Roussy, Villejuif, France Guest: Dr Cristina Ligia Cebotaru, Institute of Oncology 'Prof Dr Ion Chiricuta' Department of Radiotherapy-Medical Oncology, Cluj Napoca Guest: Dr. Paul Kubelac, Department of Medical Oncology, Institute of Oncology Cluj-Napoca-Romania

Biomarkers are essential in lung cancer treatment, but they remain underutilized. In addition, clinicians and patients have to wait for those results before starting therapy. In this episode of Lung Cancer Considered, host Dr. Stephen Liu guides a discussion about biomarkers and some of the challenges and issues they create.

This episode of Lung Cancer Considered discusses first-line treatment options for EGFR mutant NSCLC, in Italian. Guest: Dr. Jessica Menis is a thoracic medical oncologist with expertise in early-phase trials and drug development from Azienda Ospedaliera Universitaria Integrata Verona. Jessica, welcome to the podcast. Guest: Professor Filippo de Marinis is from Istituto Europeo di Oncologia, where he is Direttore della Divisione di Oncologia Toracica, and the president of Associazione Italiana Oncologia Toracica.

In this episode of Lung Cancer Considered, host Dr. Stephen Liu discusses the recently approved bispecific T-cell engager, tarlatamab, for small cell lung cancer. Guest: Dr. Anne-Marie Dingemans is a pulmonologist and Professor of Thoracic Oncology at Erasmus Medical Center in Rotterdam, the Netherlands. Guest: Dr.Ryan Gentzler is an Associate Professor and Director of the Thoracic Oncology Clinical Research Program at the University of Virginia

In episode two summarizing important lung cancer data presented at ASCO 2024, Lung Cancer Considered hosts Dr. Narjust Florez and Dr. Stephen Liu cover the phase III CROWN trial, ROS1 NSCLC with a novel ROS1 TKI, taletrectinib, the MARIPOSA trial, the PALOMA-3 trial, the WU-KONG1 data, the BEAMION-Lung1 trial, and CheckMate 77T. Guest: Dr. Clarissa Mathias is the Director of NOB/Oncoclinicas in Brazil, a member of the ASCO International Quality Steering Group and Lung Cancer Committee, and a previous IASLC Board Member. Guest: Dr. Delvys Rodriguez-Abreu is the Head of Medical Oncology at Hospital Universitario Insular de Gran Canaria and President of the Canarian Lung Cancer Foundation.

Title: ASCO 2024 Highlights Part 1 - Plenary Description: ASCO 2024 had so much lung cancer data, two podcast episodes are required to cover all the data presented. In this first episode, hosts Dr. Stephen Liu and Dr. Narjust Florez cover the LAURA trial, the ADAURA trial, the KRYSTAL-12 study, the phase III EVOKE-01 trial, the phase III ADRIATIC trial, and the REACH-PC trial. Guest: Dr. David Spigel is the Chief Scientific Officer at Sarah Cannon Research Institute and recipient of the IASLC Heine H. Hansen Lectureship for SCLC. Guest: Dr. Lecia Sequist is the Program Director for Cancer Early Detection & Diagnostics at Massachusetts General Cancer Center and the Landry Family Professor of Medicine in the Field of Medical Oncology at Harvard Medical School.

Host Dr. Stephen Liu moderates a discussion of lung cancer screening using low dose CT scans. Low dose CT scans have been shown to detect lung cancer earlier and significantly improve lung cancer mortality. Yet they remain underutilized and are only being used to detect certain types of lung cancer, specifically, smoking-related lung cancer. Guest: Dr. Pan-Chyr Yang is a Professor and former President of National Taiwan University College of Medicine and recipient of the IASLC Joseph W. Cullen Prevention & Early Detection Award at the 2020 WCLC. Guest: Dr. Elaine Shum is an Assistant Professor of Medicine at New York University Grossman School of Medicine and Principle Investigator of the Female Asian Nonsmoker Screening Study (FANSS), for which she received the Distinguished Young Investigator Research Award from the EGFR Resisters Summit.

May 31st is World No Tobacco Day and to observe this, Lung Cancer Considered host Dr. Narjust Florez leads a discussion on smoking cessation and how to honor the need for smoking cessation counseling without contributing to stigma. Smoking tobacco products (primarily cigarettes) is an important risk factor for the development of lung cancer and secondhand smoke is also a significant cause of lung cancer. Worldwide, smoking accounts for approximately two-thirds of lung cancer cases

LCC in French Canadian by IASLC

In this virtual tumor board episode, host Dr. Stephen Liu leads a discussion about the management of metastatic, PD-L1 low NSCLC. Dr. Apar Ganti is a Professor of Medicine at the University of Nebraska Medical Center and the Associate Director for Clinical Research at the Fred and Pamela Buffett Cancer Center in Omaha, Nebraska. Dr. Sze-Wai Chan from the Sandton Oncology Centre in Johannesburg, South Africa, where she is the Director and Head of Clinical Trial Research.

In this episode of Lung Cancer Considered, host Dr. Narjust Florez moderates a discussion about adenosquamous cell carcinoma of the lung, from diagnosis, treatment, and outcomes in this group of patients.

In this episode of Lung Cancer Considered, host Dr. Stephen Liu discusses KRAS mutant non-small cell lung cancer, other than G12C. This form of lung cancer varies by geography and incidence. KRAS mutations were once thought undruggable, but KRAS inhibitors are now available. However, not all forms of KRAS mutant lung cancers are the same and clinicians need to be aware of the difference between KRAS mutations.

In the wake of the FDA's approval of alectinib for resected non-small cell lung cancer, Lung Cancer Considered host Dr. Narjust Florez and Dr. Benjamen Solomon discuss this development and take a deeper look at the ALINA trial, which played an important role in the drug's approval.

As part of the IASLC’s 2024 DEI Initiative, the association is gathering member insights through an online survey and a series of virtual focus groups designed to help the organization better understand the challenges and areas for opportunity facing the global thoracic oncology profession. To take the survey, visit: https://www.iaslc.org/support-mission/iaslc-dei-initiative-global-member-surve

In this episode of Lung Cancer Considered, host Dr. Narjust Florez leads a discussion on the FLAURA2 study and changes in the first line treatment of EGFR NSCLC with guests Dr. Pasi Jänne and Dr. Marcelo Corassa. FLAURA2 was first presented at the 2023 WCLC in Singapore by Dr. Jänne.

This episode of Lung Cancer Considered covers the recently completed European Lung Cancer Congress held in Prague. Host Dr. Stephen Liu discusses the important research presented at the meeting with Dr. Jeff Bradley, Dr. Hazel O’Sullivan, and Dr. Antonio Calles.

Small cell lung cancer is a challenging subtype of lung cancer to treat because most patients present with extensive-stage disease. Unlike non-small cell lung cancer, treatments are more limited. Fortunately, the field continues to advance and there are several novel agents showing promise. In this episode of Lung Cancer Considered, host Dr. Stephen Liu discusses some of these promising therapies with Dr. Anne Chiang and Dr. Luis Paz-Ares.

This episode of Lung Cancer Considered focuses on radiopharmaceuticals-- a unique class of drugs that may have the most immediate impact in neuroendocrine tumors. Host Dr. Stephen Liu leads a discussion with three respected international clinicians about how these therapies play a role in both diagnostics and therapeutics and how they may soon be expanding.

Amivantamab Approved by FDA today, March 1! In this episode of Lung Cancer Considered, host Dr. Stephen Liu leads a discussion on the FDA approval of first-line amivantamab plus chemotherapy for NSCLC with an EGFR exon 20 insertion, based on the phase III PAPILLON trial. These data were first shared at ESMO 2023 in Madrid with a simultaneous publication in the New England Journal of Medicine.

Today’s episode of Lung Cancer Considered is part of our special series on seminal trials in thoracic oncology, focusing on the phase I study of the PD-1 inhibitor nivolumab. Hosts Dr. Narjust Florez and Dr. Stephen Liu discuss that study with guest Dr. Julie Brahmer from Johns Hopkins University. This podcast features surprise guest interviews with several doctors who were mentored by Dr. Brahmer.

ALK fusions represent 3-5% of newly diagnosed non-small cell lung cancers but several therapeutic options do exist. Lung Cancer Considered host Dr. Narjust Florez and guests Dr. Christine Lovly from Vanderbilt University and Yvonne Diaz from Oncogene Cancer Research discuss how an ALK positive diagnosis is made and what therapies are currently available to treat it.

Lung Cancer Considered Host Dr. Stephen Liu moderates a discussion in this podcast on RET as a therapeutic target. RET fusions are a known actionable alteration and this field has blossomed very quickly. He is joined on the podcast by Dr. Oliver Gautschi from the University of Bern and Cancer Center Lucerne in Switzerland and Dr. Mihaela Aldea from Gustave Roussy in France.

Today, IASLC released its 2024 Biomarker Survey, following up on its survey conducted in 2019 which found that one-third of oncologists were unaware of evidence-based guidelines for these tests. To discuss the importance of this survey and its underlying issues, host Dr. Stephen Liu discusses some of the barriers to biomarker testing with Dr. Debora Bruno, Dr. Rami Manochakian, and Dr. Matthew Smeltzer. To take the survey, visit: https://bit.ly/BiomarkerS24

Today, IASLC released its 2024 Biomarker Survey, following up on its survey conducted in 2019 that found one-third of oncologists were unaware of evidence-based guidelines for these tests. To reach a global audience, IASLC has recorded podcast episodes on this topic in different languages. In this episode, host Dr. Sally Lau leads a discussion in Cantonese about barriers to biomarker testing with Dr. Herbert Loong and Dr. Molly Li. To take the survey, visit: https://bit.ly/BiomarkerS24

Today, IASLC released its 2024 Biomarker Survey, following up on its survey conducted in 2019 which found one-third of oncologists were unaware of evidence-based guidelines for these tests. To reach a global audience, IASLC has recorded podcast episodes on this topic in different languages. In this episode, host Dr. Chunxia Su moderates a discussion in Mandarin about biomarker testing with Dr. Bo Zhu and Dr. Yuan Li. To take the survey, visit: https://bit.ly/BiomarkerS24

Today, IASLC released its 2024 Biomarker Survey, following up on its survey conducted in 2019 that found one-third of oncologists were unaware of evidence-based guidelines for these tests. To reach a global audience, IASLC has recorded podcast episodes on this topic in different languages. In this episode, host Dr. Norman Blais moderates a discussion about biomarker testing in French Canadian with Dr. Arielle Elkrief and Dr. Nicolas Marcoux. To take the survey, visit: https://bit.ly/BiomarkerS24

Today, IASLC released its 2024 Biomarker Survey, following up on its survey conducted in 2019 that found one-third of oncologists were unaware of evidence-based guidelines for these tests. To reach a global audience, IASLC has recorded podcast episodes on this topic in different languages. In this episode, host Dr. Clarissa Mathias leads a discussion in Portuguese about biomarker testing with Dr. Vladmir Lima and Dr. Aknar Calabrich. To take the survey, visit: https://bit.ly/BiomarkerS24

Today, IASLC released its 2024 Biomarker Survey, following up on its survey conducted in 2019 that found one-third of oncologists were unaware of evidence-based guidelines for biomarker tests. To reach a global audience, IASLC has recorded podcast episodes on this topic in different languages. In this episode, host Dr. Alfredo Addeo discussed barriers to biomarker testing in French with Dr. Solange Peters and Dr. Maurice Perol. To take the survey, visit: https://bit.ly/BiomarkerS24

Today, IASLC released its 2024 Biomarker Survey, following up on its survey conducted in 2019 that found one-third of oncologists were unaware of evidence-based guidelines for these tests. To promote the survey to a global audience, IASLC has recorded podcast episodes on this topic in different languages. In this episode, host Dr. Misako Nagasaka leads a discussion in Japanese about biomarker testing with Dr.Terufumi Kato and Dr. Masahiro Tsuboi. To take the survey, visit: https://bit.ly/BiomarkerS24

Today, IASLC released its 2024 Biomarker Survey, following up on its survey conducted in 2019 that found one-third of oncologists were unaware of evidence-based guidelines for these tests. To reach a global audience, IASLC has recorded podcast episodes on this topic in different languages. To discuss the importance of this survey and its underlying issues, host Dr. Narjust Florez discusses some of the barriers to biomarker testing in Spanish with Dr. Ivy Riano and Dr. Teresa Gorría. To take the survey, visit: https://bit.ly/BiomarkerS24

2024 is the 50th anniversary of the International Association for the Study of Lung Cancer and as we enter this monumental year for IASLC, we do so under a new strategic plan. To discuss what the future of IASLC looks like, hosts Dr. Stephen Liu and Dr. Narjust Florez interview four IASLC leaders to provide a glimpse into where the association is headed.

Internationally respect oncologists with deep expertise in lung cancer in the Middle East discuss, in Arabic, the role of smoking in lung cancer as well as how new targeted therapies and immunotherapies assist oncologists as they treat patients with lung cancer.

Host Dr. Sally Lau, Thoracic Medical Oncologist and Assistant Professor at the New York University Perlmutter Cancer Center, leads a discussion, in Cantonese, about biomarker testing in lung cancer and the management of EGFR mutant NSCLC.

Host Dr. Narjust Florez interviews new IASLC Chief Scientific Officer Dr. Jennifer King. In this podcast episode, Dr. King shares her perspective on how she intends to direct, guide, and support the scientific strategy of the IASLC.

Internationally respect oncologists with deep expertise in lung cancer in the Middle East discuss, in Arabic, the role of smoking in lung cancer as well as how new targeted therapies and immunotherapies assist oncologists as they treat patients with lung cancer.

In Part Two of this Lung Cancer Considered podcast on Oligometastic NSCLC, host Dr. Narjust Florez and guest Dr. Daniel Gomez discuss treatment alternatives with local therapy, focusing on radiation.

Lung Cancer Considered hosts Dr. Narjust Florez and Dr. Stephen Liu host this retrospective look at the podcast, examining how the podcast started, how the team plans podcasts and what is in store for its future.

In Part 1 of a two-part podcast on Oligometastatic lung cancer and the treatment alternatives with local therapy, host Dr. Narjust Florez interviews Dr. Fatima Wilder about how local therapies, such as surgery, radiation and cryoablation impact treatment of this complex form of lung cancer.

In this episode of Lung Cancer Considered, host Dr. Narjust Florez and guests discuss the importance of palliative care and psychological support for patients with lung cancer. Due to recent advances in lung cancer, we have reached a historic number of lung cancer survivors. Now more than ever, we need to ensure that patients receive appropriate support as they learn to live with lung cancer, lung cancer stigma, associated treatment side effects, and the idea of early mortality.

IASLC Chronic Toxicity From Targeted Therapy by IASLC

Lung cancer experts in Korea discuss the unique challenges they face when treating patients with lung cancer with EGFR and non-small cell lung cancer.

In this episode, host Dr. Stephen Liu leads a discussion on the current first-line treatment options for EGFR-mutant non-small cell lung cancer, including how new data from FLAURA2 and MARIPOSA may influence treatment approaches.

IASLC Lung Cancer Considered host Dr. Narjust Florez interviews two researchers presenting at the North America Conference on Lung Cancer: Dr. Carolyn Presley is an Associate Professor in the Division of Medical Oncology/Department of Internal Medicine at The Ohio State University, Comprehensive Cancer Center and The James Cancer Hospital/Solove Research Institute. Alexandra Potter is co-founder and President of the American Lung Cancer Screening Initiative.

Lung Cancer Considered host Dr. Stephen Liu moderates a discussion on the November 15, 2023, US FDA approval of repotrectinib for advanced NSCLC with a ROS1 gene fusion based on the single-arm, multi-cohort TRIDENT-1 trial.

Host Dr. Narjust Florez leads a discussion about the data from the KEYNOTE 671 trial, presented at ASCO 2023 and ESMO 2023, that led to the first approval of the combination of pembrolizumab plus chemotherapy in the neoadjuvant and adjuvant setting.

Sexual health of patients with lung cancer is poorly understood, highly prevalent, and not frequently discussed. However, sexual concerns are common in people with lung cancer, with many receiving very little information compared to patients diagnosed with cancer that affects a sexual or reproductive organ. In this episode of Lung Cancer Considered, host Dr. Narjust Florez leads a discussion with two national experts on how patients with lung cancer can maintain their sexual health during and after lung cancer diagnosis and treatments.

In this episode of Lung Cancer Considered, host Dr. Stephen Liu leads a discussion on the role of neoadjuvant therapy for stage III NSCLC using a virtual tumor board format. This area has become increasingly complex of late, as we have seen several large studies report encouraging results with peri-operative immunotherapy and targeted therapy.

This episode of Lung Cancer Considered covers the current treatment and research landscape in The Netherlands. The episode is recorded in Dutch and is hosted by Dr. Lizza Hendriks from the Maastricht University Medical Center. Guests are Anne Marie Dingemans from Erasmus MC, Rotterdam, The Netherlands and Anthonie Vd Wekken from the University Medical Centre Groningen.

Lung Cancer Considered host Dr. Narjust Florez leads an informed discussion on the AEGEAN Trial, which explored neoadjuvant durvalumab plus chemotherapy followed by adjuvant durvalumab in patients with resected NSCLC.

Title: Lung Cancer Care in India: Approaching a Lung Cancer Diagnosis (Hindi language podcast) The podcast is recorded in Hindi and covers a range of crucial lung cancer topics, including the emergence of adenocarcinoma as the dominant histological type, delays in diagnosis related to misdiagnosis as tuberculosis, and the importance of accurate staging and biomarker testing.

In this podcast, host Dr. Stephen Liu moderates a discussion a recent FDA approval and a specific molecular subtype of NSCLC. On October 11, 2023, the US FDA granted approval to encorafenib and binimetinib for advanced NSCLC harboring a BRAF V600E mutation based on the phase II PHAROS trial.

Part 2 of our podcast coverage on ESMO 2023 includes an in-depth interview with Dr. Jarushka Naidoo on early-stage NSCLC, including updates from CheckMate816, Keynote 671 overall survival results, and Checkmate77T, first perceptions about the data, remaining unanswered questions and how to incorporate to our clinical practice. Further, we discussed exciting data in the 2nd line setting for Small-Cell Lung Cancer and a new potential therapeutic option for thymic carcinoma. Tune in for this thought-provoking, data-driven, and practical episode of Lung Cancer Considered.

In the first part of two podcasts covering recent data presented at the European Society of Medical Oncology Congress 2023, host Dr. Stephen Liu summarizes the most compelling research on metastatic non small cell lung cancer from the meeting with Dr. Zosia Piotrowska and Dr. Noemi Reguart, discussing several impactful studies including MARIPOSA, MARIPOSA-2, LIBRETTO-431, TROPION-Lung01 and more as well as reviewing the importance of CNS efficacy and the evolving role of antibody drug conjugates (ADCs).

Today’s episode of Lung Cancer Considered is recorded entirely in Japanese and focuses on EGFR mutated lung cancer.

In this special episode of Lung Cancer Considered recorded in Hungarian, lung cancer experts in Hungary and the United States discuss challenges and emerging strategies to treat lung cancer in Hungary.

Mesothelioma is a particularly challenging cancer to treat and there had been relatively few updates in its management until the recent integration of immunotherapy into treatment guidelines. To discuss current strategies to treat Mesothelioma, Dr. Stephen Liu leads an informed discussion with two international Mesothelioma experts.

In this episode of Lung Cancer Considered, hosts Dr. Narjust Florez and Dr. Stephen Liu preview the 2023 North America Conference on Lung Cancer, scheduled for December in Chicago, December 1 - 3. The deadline for abstract submission is October 26th. Visit https://www.iaslc.org/2023-north-america-conference-lung-cancer to learn more.

Lung Cancer Considered Hosts Dr. Narjust Florez and Dr. Stephen Liu wrap up WCLC 2023 in Singapore, discussing the meeting's most impactful research, including MARS2, FLAURA2, TRIDENT, HERTHENA, and TROPION.

Lung Cancer Considered hosts Dr. Narjust Florez and Dr. Stephen Liu recap three important sessions from Tuesday, September 12th at the IASLC WCLC 2023: Advocates Unite to Increase Lung Cancer Research Funding An update on the AEGEAN Trial--Surgical Outcomes with Neoadjuvant Durvalumab + Chemotherapy Followed by Adjuvant Durvalumab in Resectable Long-term Outcomes by Radiation Technique for Locally Advanced Non-Small Lung Cancer: A Secondary Analysis of NRG Oncology-RTOG 0617 at 5-years

MARS 2 in Spanish--Monday WCLC Highlights In this Spanish-language podcast, Lung Cancer Considered Host Dr. Narjust Florez enlists two colleagues to discuss the MARS 2: A Multicentre Randomized Trial Comparing (Extended) Pleurectomy Decortication versus No Radical Surgery for Mesothelioma. Guests: Dra. Rosanna Ruiz, Oncologo clínico Institutio nacional de enfermedades neoplásicas, Lima, Peru Dr. Ricardo Terra, Cirujano toracico Professor, the cirugia toracica en la universidad de Sao Paolo, Brazil

Monday at WCLC 2023 features the Presidential Symposium. In this special WCLC 2023 episode of Lung Cancer Considered, hosts Dr. Narjust Florez and Dr. Stephen Liu talk with Dr. Eric Lim about MARS 2: A Multicentre Randomized Trial Comparing (Extended) Pleurectomy Decortication versus No Radical Surgery for Mesothelioma. Dr. Paula Ugalde, discussant for MARS 2, provides her unique overview and perspective on research presented today. The hosts also talk with Dr. P.C. Yang about the new results presented in the TALENT study of lung cancer screening in Taiwan. Emi Bossio, a patient research advocate and board member of Lung Cancer Canada adds her unique perspective. Additionally, Dr. Pasi Janne summarizes his presidential abstract: Osimertinib With/Without Platinum-Based Chemotherapy as First-line Treatment in Patients with EGFRm Advanced NSCLC (FLAURA2) and is joined in a discussion with Emi Bossio, a patient with EGFR lung cancer. Professor Eric Lim is a Consultant Thoracic Surgeon at the Royal Brompton Hospital and Professor of Thoracic Surgery at the National Heart and Lung Institute of Imperial College London. Pan-Chyr Yang, MD, PhD--National Taiwan University College of Medicine and National Taiwan University Hospital, Institute of Biomedical Sciences, Genomics Research Center, Academia Sinica, Taiwan. Paula Ugalde – Dr. Paula Ugalde Figueroa, Thoacic Surgeon, Brigham and Women's Hospital Pasi Jänne is the Director of the Lowe Center for Thoracic Oncology at Dana-Farber Cancer Institute and a Professor of Medicine at Harvard Medical School and the David M. Livingston, MD Chair at Dana-Farber Cancer Institute

Sunday highlights from WCLC 2023 include hosts Dr. Narjust Florez and Dr. Stephen Liu discussing two-year data from KRYSTAL-1 with Dr. Shirish Gadgeel; a discussion of the IASLC Language Guide and patient-centered language with noted lung cancer patient advocate Jill Feldman; and six-year follow-up data from CheckMate 227 with Dr. Solange Peters. Panelists: Shirish Gadgeel, MD is the Associate Director of Henry Ford Cancer Institute and the Chief of Division of Hematology/Oncology at Henry Ford Health. He is also Professor of Internal Medicine at Michigan State University. Jill Feldman, Lung Cancer Patient and Advocate, Twitter: Solange Peters, MD, PhD Chair and Professor, Medical Oncology, Full Professor, University Hospital of Lausanne, Lausanne, Switzerland.

From lung cancer in women to gender equity in the healthcare workforce, IASLC is privileged to host HRH Princess Dina Mired of Jordan at the 2023 World Conference on Lung Cancer. In this special episode of Lung Cancer Considered, host Dr. Narjust Florez, IASLC President Dr. Heather Wakelee, and WCLC 2023 co-chair Dr. Fiona Hegi-Johnson discuss global advocacy through a gender equity lens, lessons learned from the field, and how HRH Dina Mired’s experience as the mother of a cancer survivor has impacted her work and initiatives globally.

In this episode of Lung Cancer Considered, host Dr. Stephen Liu discusses targeted therapies, what they are, and how they have changed our approach to treating not just lung cancer, but cancers in general. Guest: Dr. Vivek Subbiah Dr. Subbiah is the Chief of Early Phase Drug Development for Sarah Cannon Research Institute. He was previously the Executive Director of Medical Oncology Research for the MD Anderson Cancer Network, where he played a pivotal role in the development and ultimate approval for several agents that we consider essential in the lung cancer world.

In this epidose of Lung Cancer Considered, Dr. Narjust Florez leads a discussion on the journey to an oncology fellowship. Medical training is long, full of sacrifices and student debt for many. For our listeners, after graduating from pre-med or undergraduate studies future physicians need to complete 4 years of medical school, followed by 3 years of internal medicine residency or 5 years of surgery or radiation oncology residency. For internal medicine residents they need to complete 3 to 4 additional years of hematology and oncology fellowship. Today we will be discussing recommendations for a smooth search, transition, and completion of an oncology fellowship. Guests: Dr. Christine Garcia, thoracic medical oncologist and fellowship program director at Weill Cornell Medicine in NYC. Dr. Regina Barragan-Carrillo, who completed her medical oncology fellowship in the Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán in Mexico City and is currently a research fellow at City of Hope. Dr. Jennifer Marks, chief oncology fellow at Georgetown University with a focus on thoracic oncology.

Lung Cancer Care in Mandarin: EGFR in China - From Testing to Treating by IASLC

Artificial intelligence is one of the most significant trends in most parts of society. Increasingly, oncologists and lung cancer researchers are including AI in research and patient care. In this episode of Lung Cancer Considered, host Dr. Narjust Florez leads a discussion of this compelling technology, focusing on its promise and limitations. Guests: Dr. Sanja Dacic, MD, PhD, MSc, an internationally renowned and highly accomplished leader in anatomic pathology and the Vice Chair and Director of Anatomic Pathology in the Department of Pathology at Yale School of Medicine. She currently serves as president of the Pulmonary Pathology Society. Dr. Fabio Ynoe de Moraes, MD, PhD, MBA - an Associate Professor and clinical investigator in radiation and global oncology at the Queen’s University and Kingston Health Sciences Centre, Kingston, ON, Canada. Dr Moraes has more than one hundred published peer-reviewed articles (i.e., NEJM, Lancet Oncology, Nature Medicine, Nature Biotechnology) and holds a PhD in Health Sciences (Oncology) and post graduate degree in artificial intelligence and machine learning and is one of the upcoming IASLC 2024 WCLC Chairs.

Greece ranks third in mortality in Europe from lung cancer, surpassed by Hungary and Serbia. In this episode of Lung Cancer Considered, host Dr. Giannis Mountzios, Director of the 4th Oncology Department and Clinical Trials Unit at the Henry Dunant Hospital in Athens, Greece, leads a discussion on the efforts from the Hellenic scientific community to implement smoking cessation strategies, screening programs, multidisciplinary approach and personalized treatment approaches of the Greek patient with lung cancer. Guests include: Helena Linardou is a Medical Oncologist, is Director of the 4th Oncology Dept and the Comprehensive Clinical Trials Center of Metropolitan Hospital in Athens, Greece. She completed a research Fellowship in Oncology and obtained her PhD Degree from Imperial College, University of London, UK Konstantinos Leventakos is a Medical Oncologist, assistant Professor at the Mayo Clinic in Rochester, USA, with a focus on thoracic malignancies, personalized medicine and immunotherapy.

This episode of Lung Cancer Considered previews the upcoming IASLC Hot Topic in Basic and Translational Science Meeting on Resistance to Immunotherapy in NSCLC. Joining host Dr. Stephen Liu are: Guests: Dr. Joachim Aerts, Professor of Pulmonary Oncology at Erasmus University Rotterdam and Head of Pulmonary Medicine at Erasmus MC in the Netherlands. Dr. Kellie Smith, Associate Professor of Oncology at Johns Hopkins University. Dr. Roberto Ferrara, Medical Oncologist and Immunologist, from Istituto Nazionale dei Tumori di Milano in Milan, Italy.